Subscribe to RSS
DOI: 10.1055/s-0034-1399755
Eyes on MEGDEL: Distinctive Basal Ganglia Involvement in Dystonia Deafness Syndrome
Publication History
01 September 2014
25 November 2014
Publication Date:
02 February 2015 (online)
Abstract
Pediatric movement disorders are still a diagnostic challenge, as many patients remain without a (genetic) diagnosis. Magnetic resonance imaging (MRI) pattern recognition can lead to the diagnosis. MEGDEL syndrome (3-MethylGlutaconic aciduria, Deafness, Encephalopathy, Leigh-like syndrome MIM #614739) is a clinically and biochemically highly distinctive dystonia deafness syndrome accompanied by 3-methylglutaconic aciduria, severe developmental delay, and progressive spasticity. Mutations are found in SERAC1, encoding a phosphatidylglycerol remodeling enzyme essential for both mitochondrial function and intracellular cholesterol trafficking. Based on the homogenous phenotype, we hypothesized an accordingly characteristic MRI pattern. A total of 43 complete MRI studies of 30 patients were systematically reevaluated. All patients presented a distinctive brain MRI pattern with five characteristic disease stages affecting the basal ganglia, especially the putamen. In stage 1, T2 signal changes of the pallidum are present. In stage 2, swelling of the putamen and caudate nucleus is seen. The dorsal putamen contains an “eye” that shows no signal alteration and (thus) seems to be spared during this stage of the disease. It later increases, reflecting progressive putaminal involvement. This “eye” was found in all patients with MEGDEL syndrome during a specific age range, and has not been reported in other disorders, making it pathognomonic for MEDGEL and allowing diagnosis based on MRI findings.
-
References
- 1 Wortmann S, Rodenburg RJ, Huizing M , et al. Association of 3-methylglutaconic aciduria with sensori-neural deafness, encephalopathy, and Leigh-like syndrome (MEGDEL association) in four patients with a disorder of the oxidative phosphorylation. Mol Genet Metab 2006; 88 (1) 47-52
- 2 Sarig O, Goldsher D, Nousbeck J , et al. Infantile mitochondrial hepatopathy is a cardinal feature of MEGDEL syndrome (3-methylglutaconic aciduria type IV with sensorineural deafness, encephalopathy and Leigh-like syndrome) caused by novel mutations in SERAC1. Am J Med Genet A 2013; 161A (9) 2204-2215
- 3 Wortmann SB, Vaz FM, Gardeitchik T , et al. Mutations in the phospholipid remodeling gene SERAC1 impair mitochondrial function and intracellular cholesterol trafficking and cause dystonia and deafness. Nat Genet 2012; 44 (7) 797-802
- 4 Dahl HH. Getting to the nucleus of mitochondrial disorders: identification of respiratory chain-enzyme genes causing Leigh syndrome. Am J Hum Genet 1998; 63 (6) 1594-1597
- 5 Dweikat IM, Abdelrazeq S, Ayesh S, Jundi T. MEGDEL Syndrome in a Child From Palestine: report of a Novel Mutation in SERAC1 Gene. J Child Neurol 2014; ; doi: 10.1177/0888073814541474
- 6 Tort F, García-Silva MT, Ferrer-Cortès X , et al. Exome sequencing identifies a new mutation in SERAC1 in a patient with 3-methylglutaconic aciduria. Mol Genet Metab 2013; 110 (1–2) 73-77
- 7 Karkucinska-Wieckowska A, Lebiedzinska M, Jurkiewicz E , et al. Increased reactive oxygen species (ROS) production and low catalase level in fibroblasts of a girl with MEGDEL association (Leigh syndrome, deafness, 3-methylglutaconic aciduria). Folia neuropathologica/Association of Polish Neuropathologists and Medical Research Centre. Polish Academy of Sciences 2011; 49 (1) 56-63
- 8 López LC, Schuelke M, Quinzii CM , et al. Leigh syndrome with nephropathy and CoQ10 deficiency due to decaprenyl diphosphate synthase subunit 2 (PDSS2) mutations. Am J Hum Genet 2006; 79 (6) 1125-1129
- 9 Jareño NM, Fernández-Mayoralas DM, Silvestre CP, Cortés BM, Pérez MU, Campos-Castelló J. 3-methylglutaconic aciduria type 4 manifesting as Leigh syndrome in 2 siblings. J Child Neurol 2007; 22 (2) 218-221
- 10 Harting I, Neumaier-Probst E, Seitz A , et al. Dynamic changes of striatal and extrastriatal abnormalities in glutaric aciduria type I. Brain 2009; 132 (Pt 7) 1764-1782
- 11 Loupatty FJ, van der Steen A, Ijlst L , et al. Clinical, biochemical, and molecular findings in three patients with 3-hydroxyisobutyric aciduria. Mol Genet Metab 2006; 87 (3) 243-248
- 12 Sasaki M, Yamada N, Fukumizu M, Sugai K. Basal ganglia lesions in a patient with 3-hydroxyisobutyric aciduria. Brain Dev 2006; 28 (9) 600-603
- 13 Sass JO, Walter M, Shield JP , et al. 3-Hydroxyisobutyrate aciduria and mutations in the ALDH6A1 gene coding for methylmalonate semialdehyde dehydrogenase. J Inherit Metab Dis 2012; 35 (3) 437-442
- 14 Draganski B, Kherif F, Klöppel S , et al. Evidence for segregated and integrative connectivity patterns in the human Basal Ganglia. J Neurosci 2008; 28 (28) 7143-7152